Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer

BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Belbaraka, Rhizlane, Trédan, Olivier, Ray-Coquard, Isabelle, Chvetzoff, Giselle, Bajard, Agathe, Pérol, David, Ismaili, Nabil, Ismaili, Mohammed, Errihani, Hassan, Bachelot, Thomas, Rebattu, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904794/
https://www.ncbi.nlm.nih.gov/pubmed/20537187
http://dx.doi.org/10.1186/1756-0500-3-164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904794/
https://www.ncbi.nlm.nih.gov/pubmed/20537187
http://dx.doi.org/10.1186/1756-0500-3-164

Ejemplares similares